Upstream Bio, Inc. UPB
3.60 USD +0.21 (+6.19%)
Nov 4, 2026, 10:58 AM EST
3.52 Day range 3.81
2.68 52-week range 33.68
- YTD
- -86.74%
- 1 year
- -85.62%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.86 +1229.4% upside
Now 3.60
- Target (low)
- 35.00
- Target (mean)
- 47.86
- Target (high)
- 75.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 8
- 3 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.76667 | -0.79 – -0.74 | -0.51 | -50.3% | 604.00K | +6.7% | 3 |
| Next quarter | -0.71 | -0.75 – -0.69 | -0.74 | +4.0% | 606.50K | -35.3% | 3 |
| Current year | -2.82 | -2.89 – -2.75 | -2.66 | -5.9% | 1.21M | -57.7% | 3 |
| Next year | -3.52 | -5.33 – -2.07 | -2.82 | -24.9% | 1.22M | +0.8% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 27, 2026 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Dec 18, 2025 | Mizuho | Initiated | — | Outperform |
| Dec 2, 2025 | LifeSci Capital | Initiated | — | Outperform |
| Nov 18, 2025 | Evercore ISI Group | Initiated | — | Outperform |
| Oct 14, 2025 | Truist Securities | Initiated | — | Buy |
| Nov 5, 2024 | JP Morgan | Initiated | — | Overweight |
| Nov 5, 2024 | William Blair | Initiated | — | Outperform |
| Nov 5, 2024 | TD Cowen | Initiated | — | Buy |
| Nov 5, 2024 | Piper Sandler | Initiated | — | Overweight |